eFFECTOR Therapeutics Inc · OTC:EFTR
eFFECTOR Therapeutics — SPAC Merger (May 2021)
50 slides from eFFECTOR Therapeutics's SPAC merger presentation, May 27, 2021
Slide 1: Corporate Overview May 2021
Corporate Overview May 2021 Next Generation Targeted Therapy for Cancer Exhibit 99.2
Slide 2: Disclaimer
Disclaimer 1 ABOUT THIS PRESENTATION This presentation is for informational purpose sonly to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Locust Walk Acquisition Corp. (LWAC) and eFFECTOR Therapeutics, Inc
Slide 3: Executive Summary
EXECUTIVE SUMMARY Pioneering Selective Translation Regulator Inhibitors (STRIs) – a leading company targeting MNK and eIF4F complex MNK drives production of checkpoint proteins including PD-1, PD-L1, LAG-3 and TIM-3 eIF4F is a key node where the RAS and PI3K pathways converge to drive production of
Slide 4: eFFECTOR Meets Demanding Criteria of Locust Walk Acquisition Corp
eFFECTOR MEETS DEMANDING CRITERIA OF LOCUST WALK ACQUISITION CORP Locust Walk Acquisition Corp (LWAC) is a $175M SPAC focused on biotechnology with a comprehensive investment thesis that has been used to evaluate over 90 potential targets SUPERLATIVE CRITERIA Validating Partnership Novel Lead Asset
Slide 5: eFFECTOR Pipeline: Multiple STRIs in development
eFFECTOR Pipeline: Multiple STRIs in development Program (Target) Discovery Preclinical Phase 1 Phase 2 Phase 3 Global Rights Anticipated Milestones U.S. addressable population Tomivosertib (MNK 1/2i) Zotatifin (elF4Ai) eIF4Ei NSCLC – 1L Extension in combo with pembro Solid Tumors RTK BC and KRAS NS
Slide 6: Targeting Key Node in Cancer Controlling Cell Growth and Proliferation
Targeting Key node in cancer controlling Cell Growth and proliferation eIF4F complex is a central node where two highly validated cancer pathways converge to activate production of onco-proteins involved in growth, proliferation and survival of tumor cells MNK activates eIF4F and drives T cell exhau
Slide 7: Platform, chemistry, culture and upcoming value inflection events
Foundation Platform – mRNA translation biology from UCSF Chemistry – world class SBDD expertise Culture – rigorous science and capital efficiency Next 12-24 months Tomi – definitive PoC for pembro combination Zota – ORR data from expansion cohorts Zota COVID – obtain human antiviral PoC data eIF4E –
Slide 8: Experienced leadership team and scientific advisors
Steve Worland, Ph.D. Founder, President, CEO and Director Premal Patel, M.D., Ph.D. CMO Alana McNulty CBO Mike Byrnes CFO Experienced leadership team Scientific Advisors Institution Expertise Kevan Shokat, PhD UCSF, eFFECTOR Co-founder Translation & KRAS Davide Ruggero, PhD UCSF, eFFECTOR Co-founder
Slide 9: Tomivosertib (eFT508)
Tomivosertib (eFT508) Designed to stimulate activation, prevent exhaustion and prolong memory of T cells MNK 1/2 Inhibitor
Slide 10: Tomivosertib – inhibiting MNK 1/2 kinase promotes T cell activity
T Cells Continuous activation of TCR leads to feedback mechanisms involving MNK that result in T cell exhaustion/dysfunction Delaying or reversing T cell exhaustion is a highly sought-after attribute in new IO products to extend benefit of PD-(L)1 agents Highly selective MNK inhibitor, tomivosertib,
Slide 11: Tomivosertib Triggered Anti-Tumor Activity and Enhanced PD-1 Blockade In Vivo
TOMIVOSERTIB TRIGGERED ANTI-TUMOR ACTIVITY AND ENHANCED THE ACTIVITY OF PD-1 CHECKPOINT BLOCKADE IN VIVO Tumor biopsies from eFT508 treated animals showed an increased ratio of CD8+ T cells to FOXP3+ T cells (Tregs) and a decreased M2 macrophage population Tomivosertib downregulated multiple checkpo
Slide 12: Tomivosertib Clinical Overview
Tomivosertib clinical Overview* Tomivosertib was generally well tolerated at RP2D as single agent and in combination with anti-PD-(L)1 agents The most common drug-related side effects have included low grade nausea, vomiting, fatigue and tremors Safety results when combined with anti-PD-(L)1 agents
Slide 13: Tomivosertib Demonstrated Prolonged PFS with Anti-PD-(L)1 Agents
Tomivosertib demonstrated prolonged pfs when combined with anti-PD-(L)1 agents Phase 2a study combined with anti-PD-(L)1 demonstrated encouraging activity* Tomivosertib was added to patients not responding to ongoing anti-PD-(L)1 therapy with no change or break in anti-PD-(L)1 regimen Confirmed PR o
Slide 14: Phase 2a Results Suggest Potential to Reverse Resistance
Tomi + Pembro Pembro mono Transferred to individual IND phase 2a results suggest tomivosertib’s potential to reverse resistance to anti-PD-(L)1 therapy Data through study completion in September 2020. Includes all evaluable patients with at least one on treatment scan (n=16). Patients 115-103 and 12
Slide 15: Patient on Tomi/Pembro Combo Experienced Confirmed Complete Response
Patient on Tomi/Pembro Combo Experienced Confirmed Complete Response after ~2 Years on Combo Tx
Slide 16: Demonstrated PFS in NSCLC Patients
Demonstrated PFS in NSCLC patients Median of 2 prior therapies for metastatic disease prior to addition of tomivosertib Median PFS = 20 weeks, mOS 19.0 months 9 of 17 patients (53%) remained on study ≥ 24 weeks Comparator data set from OAK study Treatment Beyond Progression cohort* ─ median ~7 weeks
Slide 17: PD-L1 Positive Patients Showed Longer PFS
PD-L1 positive patients showed longer PFS Data through study completion in September 2020 Patients 115-103 and 120-103 continued treatment past study completion on Single Patient Expanded Access INDs
Slide 18: PD-L1 Positive Patients Showed Longer PFS
Pd-l1 positive patients showed longer pfs A post-hoc analysis showed that PD-L1 positive patients had three times lower risk of progression than PD-L1 negative patients in Phase 2a study In the OAK treatment beyond progression cohort, PD-L1 status was not correlated with benefit of continued treatme
Slide 19: Plan to Evaluate Novel Treatment Setting – 1L Extension NSCLC
Plan to evaluate novel treatment setting – 1L Extension Nsclc Based on our 17 NSCLC patient data, we received FDA allowance to proceed with the following 1L extension study Tomivosertib added to pembrolizumab after initial progression In patients suitable to continue on pembrolizumab after PD Contro
Slide 20: Randomized Phase 2b KICKSTART Trial Design
~ 120 patients will be enrolled in a randomized Phase 2b trial, with 2 independent cohorts: Front line extension – combo post initial PD on pembrolizumab Front line combo treatment with pembrolizumab Stage IV NSCLC PD-L1 50% No prior chemo Tomivosertib + pembrolizumab Placebo + pembrolizumab Key end
Slide 21: P2A vs P2B KICKSTART Comparison
P2A (completed) P2B KICKSTART (ongoing) Patient Population Patients were on any approved PD-(L)1 therapy and allowed prior chemo Pembrolizumab only, no prior chemo in the metastatic setting PD-L1 Status Any PD-L1 level eligible, including PD-L1 negative patients who had shorter PFS Only enrolling PD
Slide 22: Potential Market Settings – PD-L1 > 50%
Pembro Monotherapy ≥ 50% PD-L1 Advanced/Metastatic NSCLC w/ No Actionable Mutations Platinum Doublet ± Pembrolizumab Docetaxel ± Ramucirumab Lenvatinib + Pembrolizumab Sitravatinib + Nivolumab 2L salvage therapy alternatives Novel Setting: Tomi + pembro – 1L Extension (reverse resistance) US address
Slide 23: Zotatifin (eFT226) eIF4A Helicase Inhibitor – Oncology
Zotatifin (eFT226) eIF4A Helicase Inhibitor Oncology: Designed to downregulate key oncoproteins and cell cycle proteins
Slide 24: Zotatifin Designed to Inhibit Production of Key Proteins
4A- translationally regulated genes including RTKs, KRAS, ER, Cyclin D1, CDK4/6 Zotatifin DESIGNED TO inhibit production of key proteins driven by upstream oncogenes eIF4A is activated by upstream oncogenic signaling and regulates synthesis of key cell proliferation proteins In preclinical studies z
Slide 25: Preclinical Translation Regulation by Zotatifin Was Selective
Preclinical regulation of translation by zotatifin was selective for proteins that drive tumor growth and resistance Zotatifin Target Sequence KRASmut protein all forms Cell proliferation/ cycle proteins RTK proteins Control protein unaffected Non-coding sequence coding sequence Experimental structu
Slide 26: Activity Observed in ER+ and HER2+ Breast Cancer Models
Activity observed as single agent and in combination in ER+ and HER2+ breast cancer models Zotatifin was observed to down-regulate multiple proteins that drive ER+, FGFR+ and HER2+ breast cancer, including: ER, FGFR, HER2, Cyclin D1, CDK4/6 In tumors driven by more than one of these factors, zotatif
Slide 27: Single Agent and Combination Activity in KRAS NSCLC Model
SINGLE AGENT AND COMBINATION ACTIVITY OBSERVED IN KRAS NSCLC MODEL NCI-H1792 NSCLC KRASG12C – Zotatifin mono showed similar activity as AMG510 in this model – Combination led to regressions in almost all animals Zotatifin (eFT226) showed strong synergy in cell proliferation and apoptosis assays in c
Slide 28: Exposures in Dose Escalation Match Preclinical Activity
Exposures achieved in dose escalation match exposures that showed activity in preclinical models P1 dose escalation ongoing, IV once weekly Long observed half-life of ~4 days has potential to maintain target suppression with intermittent dosing Zotatifin achieved target exposures in patients that sh
Slide 29: Financial Overview
financial OVERVIEW Top-tier Life Sciences Investors 2015 Series B 2013 Series A 2017 Series C Financial Highlights AbbVie Biotech Ventures $150M raised from top tier investors Up to $507M achievable under Pfizer agreement $42M received to date $465M potential additional development and sales milesto
Slide 30: Multiple Upcoming Clinical Milestones
Multiple upcoming clinical milestones 29
Slide 31: Transaction Summary
Transaction summary eF (OR
Slide 32: Transaction Overview
TRANSACTION OVERVIEW eFFECTOR has entered into a definitive agreement to merge with Locust Walk Acquisition Corp (“LWAC”) Implied post-money enterprise value of ~$420 million Transaction to be funded through a combination of $60 million committed PIPE financing plus up to $175 million from LWAC’s ca
Slide 33: Transaction Overview: Valuation, Sources and Uses, Ownership
TRANSACTION OVERVIEW Illustrative Post-Money Valuation at Close Illustrative Estimated Transaction Cash Sources and Uses Illustrative Post-Transaction Ownership Note: Assumes eFFECTOR cash balance of $17 million and debt balance of $20 million as of March 31, 2021, a $60 million PIPE issuance at $10
Slide 34: Appendix
Appendix Fi (OR
Slide 35: Tomivosertib Is a Highly Selective MNK Inhibitor
Tomivosertib is a highly selective mnk inhibitor Tomivosertib (eFT508) was tested against > 400 protein and lipid kinases at 1 mM concentration Reich et al. J. Med. Chem. 2018 61, 3516-3540. 34
Slide 36: Tomivosertib Background – Preclinical Data Summary
tomivosertib background - Preclinical data summary 35 Tomivosertib is an immunologically active agent Downregulated expression of checkpoint proteins, including PD-1,PD-L1, LAG-3 and TIM-3 Inhibited production of immunosuppressive cytokine IL-10 without interfering with interferon-g production Funct
Slide 37: Tomivosertib Downregulates Key Immunosuppressive Factors in Activated T Cells
Tomivosertib downregulates expression of key immunosuppressive factors in activated T cells Stimulated human primary T cells OT-I cells 36
Slide 38: Tomivosertib Does Not Inhibit Interferon-g Expression
Tomivosertib does not inhibit expression of immuno-stimulatory cytokine interferon-g IFN-g expressing T cells 37
Slide 39: Tomivosertib Increased CD8+ T Cell/Treg Ratio
Tomivosertib increased ratio of CD8+ T cells/Tregs and decreased M2 macrophage population In CT-26 syngeneic model (efficacy data on slide 11), treatment with tomivosertib increased ratio of CD8+/FOXP3+ cells and decreased M2 macrophages in tumor biopsies. Collaborators from McGill University indepe
Slide 40: Tomivosertib Reprograms T Cells to Increase Central Memory Pool
Target cell killing Tomivosertib Reprograms t cells from within to increase central memory pool and enhance cytotoxic function Central memory T cells mouse human 39
Slide 41: Tomivosertib Increased T Cell Memory Pool
Tomivosertib increased the T cell memory pool and increase was maintained beyond dosing period 40
Slide 42: Zotatifin (eFT226) eIF4A Helicase Inhibitor – COVID-19
Zotatifin (eFT226) eIF4A Helicase Inhibitor COVID-19: Designed to inhibit unwinding of complex RNA structures necessary to translate SARS-CoV-2 proteins
Slide 43: Zotatifin Showed Potent In Vitro Activity Against Coronavirus Strains
Zotatifin showed potent in vitro activity against multiple coronavirus strains eIF4A is required to unwind complex RNA secondary structures within the 5’ untranslated region (5’-UTR) of SARS-CoV-2 and other RNA viruses to translate polyprotein and replicate virus Drug screen published in Nature* rep
Slide 44: Risk Factors
RISK FACTORS Risks Related to Our Limited Operating History, Financial Position and Capital Requirements We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any re
Slide 45: Risk Factors (Cont'd)
RISK FACTORS (Cont’d) Risks Related to Our Reliance on Third Parties We rely on third parties to conduct our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlin
Slide 46: Risk Factors (Cont'd)
RISK FACTORS (Cont’d) Risks Related to Our Business Operations and Industry Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. We are depende
Slide 47: Risk Factors (Cont'd)
RISK FACTORS (Cont’d) Risks Related to Our Intellectual Property If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or iden
Slide 48: Risk Factors (Cont'd)
RISK FACTORS (Cont’d) Risks Related to Becoming a Public Company We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. We will be an emerging growth company and a smaller r
Slide 49: Risk Factors (Cont'd)
RISK FACTORS (Cont’d) There is no assurance that a stockholder’s decision whether to redeem its shares for a pro rata portion of LWAC’s trust account will put the stockholder in a better future economic position. If the Business Combination’s benefits do not meet the expectations of investors or sec
Slide 50: Corporate Overview May 2021
Corporate Overview May 2021 Next Generation Targeted Therapy for Cancer